The company plans to use the funding to build beta units of its optical nanopore sequencer for early adopters in industry and academia.
The Beijing-based firm said it will use the funding for research and development, to obtain additional intellectual property, and to pursue its strategic goals.
The company had £13.8 million ($18.4 million) in revenues and a net loss of £56.6 million in 2017.
University of Oxford researchers used DNA scaffolds to build custom peptide nanopores that they said could make nanopore-based protein analysis more feasible.
CTO Clive Brown provided an overview of the new approach during a presentation at the firm's user meeting last week.
Using a protocol developed at the University of Oxford, the researchers hope that nanopore sequencing can aid diagnosis and drug resistance profiling in remote areas.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
The researchers said that a faster method could avoid having to freeze embryos and as a result may improve the success rate of in vitro fertilization.
Complex SVs played a role in four of 1,300 Mendelian disease cases analyzed, of which nanopore sequencing helped to resolve one.
The company will use the funding to build a manufacturing facility, expand commercialization efforts, and develop new products.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.